Ginkgo Biloba, Memory, and Circulation: What Do Large Trials Show?

Ginkgo biloba is a tree species that has survived on Earth in nearly unchanged form for over 200 million years — sometimes called a "living fossil." Its leaves and seeds have been used in Chinese medicine for thousands of years, but it was the standardized leaf extract, designated EGb 761 and developed by a German pharmaceutical company in the 1960s, that became the basis for the vast majority of modern clinical trials. This distinction matters: when this article says "ginkgo," it almost always means this specific standardized extract, not just any ginkgo-leaf product off a store shelf.

Ginkgo is sold today mainly on two promises: improved memory and cognitive function, and improved circulation, both cerebral and peripheral. Both promises have some mechanistic basis — but as the large clinical trials covered below show, reality is far more mixed than supplement packaging suggests.

Ginkgo extract contains two main groups of active compounds: flavonoids (antioxidant) and terpenoids, including ginkgolides unique to this plant. Ginkgolides act as platelet-activating factor (PAF) antagonists — theoretically reducing excessive platelet aggregation and improving blood rheology, which could translate into better microcirculation, including in cerebral vessels. Flavonoids, meanwhile, neutralize free radicals, which in animal models limited oxidative stress in nervous tissue.

This mechanism — improved microcirculation plus neuroprotection — is logically coherent and well documented at the cellular level and in animal models. The question large clinical trials actually answer is different, though: does this biological activity translate into a detectable, clinically meaningful improvement in memory, cognitive function, or circulation in people under everyday supplement use.

The vast majority of ginkgo supplement advertising targets healthy people with no diagnosed cognitive impairment, promising better memory, focus, and "mental clarity." It's exactly this population that one of the most comprehensive meta-analyses on the topic examined.

If ginkgo doesn't improve memory in healthy, younger people, the remaining question was whether it might at least prevent dementia in older adults — including those with already mildly impaired cognition. One of the largest and longest-running ginkgo trials ever conducted, GEM (Ginkgo Evaluation of Memory), was designed to answer exactly that.

The scale of this trial — over 3,000 participants followed for an average of more than six years — makes it one of the most credible evidence sources in the entire "memory supplement" literature. Six years is long enough to detect even a modest preventive effect, if one existed — yet no difference between groups was observed.

The picture changes, however, in a different group: patients whose mild cognitive impairment (MCI) or Alzheimer's disease has already been clinically diagnosed, and where ginkgo is used as an add-on, not a replacement, for standard treatment.

The second major marketing promise for ginkgo is improved circulation, including in patients with intermittent claudication — leg pain while walking caused by atherosclerotic narrowing of the leg arteries (peripheral arterial disease). Unlike many other ginkgo uses, this question has had a rigorous Cochrane review.

This distinction has practical implications: marketing ginkgo as a universal "memory booster" for healthy young or middle-aged people has no solid evidentiary basis, while considering it as an add-on treatment for an already-diagnosed neurodegenerative condition — after consulting the treating physician — rests on considerably firmer ground.

Putting the whole evidence base together, the most defensible use of ginkgo appears to be as an add-on to standard treatment, after consulting a neurologist or geriatrician, in patients already diagnosed with mild cognitive impairment or Alzheimer's disease — not as a standalone prevention strategy in healthy people, nor as a substitute for drug therapy. We cover other, better-established ways to support memory and cognitive function — sleep, exercise, cognitive training — more broadly in our entry on neuroplasticity.

Ginkgo biloba is a good example of a supplement where marketing got decades ahead of the science. Rigorous, multi-year trials in healthy people and for dementia prevention consistently find no effect — and that's exactly the group most of the marketing targets. The only area where the evidence is even moderately convincing is as an add-on to treatment in patients with an already-diagnosed neurodegenerative condition, and even then under medical supervision, not as a standalone "memory" strategy.